Skip to main content
大唐药业 logo

大唐药业 — Investor Relations & Filings

Ticker · 920433 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2023-05-08 Investor Presentation
Country CN China
Listing Beijing Stock Exchange 920433

About 大唐药业

http://www.nmdt.com.cn/

Inner Mongolia Datang Pharmaceutical specializes in the research, development, and production of traditional Chinese and Mongolian medicines. The company focuses on modernizing ethnic medicinal formulas through advanced biotechnology and standardized manufacturing processes. Its product portfolio covers therapeutic areas including respiratory health, cardiovascular conditions, and gastrointestinal disorders. Notable offerings include Xuanfei Zhike granules and specialized Mongolian medicinal preparations. The organization integrates traditional knowledge with contemporary clinical research to develop proprietary formulations. By maintaining rigorous quality management systems and investing in automated production lines, the company aims to enhance the efficacy and accessibility of ethnic medicines for a broad patient base.

Recent filings

Filing Released Lang Actions
2022年年度报告业绩说明会预告公告
Investor Presentation Classification · 95% confidence The document is a notice announcing a scheduled performance explanation meeting related to the company's 2022 Annual Report. It references the 2022 Annual Report that was previously disclosed and invites investors to participate in a webcast meeting to discuss the report. The document does not contain the actual annual report or detailed financial data but serves as an announcement for the upcoming investor presentation event focused on the annual report. Therefore, it fits the category of an Investor Presentation (IP) announcement rather than the Annual Report itself or a report publication announcement, as it details the meeting's time, participants, and participation method for discussing the annual report.
2023-05-08 Chinese
内蒙古上都律师事务所关于内蒙古大唐药业股份有限公司2020年第一期股权激励计划第二个解除限售期解限售条件未成就暨回购注销部分限制性股票之法律意见书
Regulatory Filings
2023-04-25 Chinese
2022年年度报告
Annual Report Classification · 100% confidence The document is titled "内蒙古大唐药业股份有限公司 2022 年年度报告" which translates to "Inner Mongolia Grand Pharmaceutical Co., Ltd. 2022 Annual Report." It contains detailed financial data, including income, profit, assets, liabilities, quarterly financial data, management discussion and analysis, risk disclosures, company overview, and other comprehensive information typical of a full annual report. The document length is 15,000 characters, indicating a full report rather than a brief announcement. There is no indication that this is merely an announcement or a certification. The presence of audited financial statements and management discussion confirms it is the official yearly report covering company activity and full financial performance for the year 2022. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2023-04-25 Chinese
独立董事关于第三届董事会第十一次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal announcement from independent directors providing their prior approval opinions on matters to be discussed at the company's board meeting. It includes opinions on the reappointment of the audit firm for 2023 and anticipated related-party transactions. The document does not contain financial statements or detailed audit results, but rather is a governance-related announcement concerning board meeting agenda items. It is not an audit report itself, nor an annual or interim report. It fits best under Board/Management Information (MANG) as it relates to board meeting matters and approvals.
2023-04-25 Chinese
2022年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled '2022 年度独立董事述职报告' which translates to '2022 Annual Independent Directors' Report'. It details the attendance and activities of independent directors during the year 2022, including their opinions on various board meeting agenda items and their efforts to protect shareholder interests. The content focuses on board/management activities and independent directors' duties rather than financial results or audit opinions. It is not an annual report, audit report, or earnings release. It is also not a simple announcement or certification but a detailed report on board/management oversight and governance activities. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is 2204 characters, which is consistent with a detailed report but not a full financial report. Confidence is high due to the clear focus on independent directors' activities and governance.
2023-04-25 Chinese
关于预计2023年日常性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's expected related party transactions for the year 2023. It includes details about the nature of the transactions, the parties involved, board and independent director approvals, and mentions that the matter will be submitted to the shareholders' meeting for approval. The document is a regulatory announcement about anticipated related party transactions rather than a financial report or detailed management discussion. It does not contain financial statements or detailed financial analysis. The document length is 2743 characters, which is relatively short and consistent with an announcement. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-04-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.